Difference between revisions of "Aminoglutethimide (Cytadren)"
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]") |
Warner-admin (talk | contribs) m (Text replacement - "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]" to "UpToDate Lexidrug") |
||
(2 intermediate revisions by the same user not shown) | |||
Line 4: | Line 4: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, [http://reference.medscape.com/drug/cytadren-aminoglutethimide-342878 Medscape], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it was used== | ==Diseases for which it was used== |
Latest revision as of 00:11, 6 July 2024
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.[1]
Diseases for which it was used
Patient drug information
History of changes in FDA indication
This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.
- 1980-10-29: Initial approval
Also known as
- Brand names: Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol